Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment

2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

Ali Taher, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler-Krahn, Ali El-Ali, Bernard Roubert, Amal El-Beshlawy

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Following 1-yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with β-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC). Seventy-eight per cent had dose increases at median of 26wk, suggesting that 1-yr results may not have reflected full deferasirox efficacy. Extension data are presented here. Deferasirox starting dose was 20mg/kg/d (increases to 30/40mg/kg/d permitted in the core/extension, respectively). Efficacy was primarily assessed by absolute change in LIC and serum ferritin. Overall, 231 patients received deferasirox in the extension; 67.4% (P

Original languageEnglish
Pages (from-to)355-365
Number of pages11
JournalEuropean Journal of Haematology
Volume87
Issue number4
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Thalassemia
Iron
Liver
Therapeutics
Ferritins
Maintenance
deferasirox
Serum

Keywords

  • β-thalassaemia
  • Deferasirox
  • Efficacy
  • Iron chelation therapy
  • Iron overload

ASJC Scopus subject areas

  • Hematology

Cite this

Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment : 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. / Taher, Ali; Elalfy, Mohsen S.; Al Zir, Kusai; Daar, Shahina; Al Jefri, Abdullah; Habr, Dany; Kriemler-Krahn, Ulrike; El-Ali, Ali; Roubert, Bernard; El-Beshlawy, Amal.

In: European Journal of Haematology, Vol. 87, No. 4, 10.2011, p. 355-365.

Research output: Contribution to journalArticle

Taher, A, Elalfy, MS, Al Zir, K, Daar, S, Al Jefri, A, Habr, D, Kriemler-Krahn, U, El-Ali, A, Roubert, B & El-Beshlawy, A 2011, 'Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia', European Journal of Haematology, vol. 87, no. 4, pp. 355-365. https://doi.org/10.1111/j.1600-0609.2011.01662.x
Taher, Ali ; Elalfy, Mohsen S. ; Al Zir, Kusai ; Daar, Shahina ; Al Jefri, Abdullah ; Habr, Dany ; Kriemler-Krahn, Ulrike ; El-Ali, Ali ; Roubert, Bernard ; El-Beshlawy, Amal. / Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment : 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. In: European Journal of Haematology. 2011 ; Vol. 87, No. 4. pp. 355-365.
@article{28f7444b85514996aa3d617abb88db8f,
title = "Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia",
abstract = "Following 1-yr deferasirox therapy in the ESCALATOR study, 57{\%} of previously chelated patients with β-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC). Seventy-eight per cent had dose increases at median of 26wk, suggesting that 1-yr results may not have reflected full deferasirox efficacy. Extension data are presented here. Deferasirox starting dose was 20mg/kg/d (increases to 30/40mg/kg/d permitted in the core/extension, respectively). Efficacy was primarily assessed by absolute change in LIC and serum ferritin. Overall, 231 patients received deferasirox in the extension; 67.4{\%} (P",
keywords = "β-thalassaemia, Deferasirox, Efficacy, Iron chelation therapy, Iron overload",
author = "Ali Taher and Elalfy, {Mohsen S.} and {Al Zir}, Kusai and Shahina Daar and {Al Jefri}, Abdullah and Dany Habr and Ulrike Kriemler-Krahn and Ali El-Ali and Bernard Roubert and Amal El-Beshlawy",
year = "2011",
month = "10",
doi = "10.1111/j.1600-0609.2011.01662.x",
language = "English",
volume = "87",
pages = "355--365",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment

T2 - 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

AU - Taher, Ali

AU - Elalfy, Mohsen S.

AU - Al Zir, Kusai

AU - Daar, Shahina

AU - Al Jefri, Abdullah

AU - Habr, Dany

AU - Kriemler-Krahn, Ulrike

AU - El-Ali, Ali

AU - Roubert, Bernard

AU - El-Beshlawy, Amal

PY - 2011/10

Y1 - 2011/10

N2 - Following 1-yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with β-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC). Seventy-eight per cent had dose increases at median of 26wk, suggesting that 1-yr results may not have reflected full deferasirox efficacy. Extension data are presented here. Deferasirox starting dose was 20mg/kg/d (increases to 30/40mg/kg/d permitted in the core/extension, respectively). Efficacy was primarily assessed by absolute change in LIC and serum ferritin. Overall, 231 patients received deferasirox in the extension; 67.4% (P

AB - Following 1-yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with β-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC). Seventy-eight per cent had dose increases at median of 26wk, suggesting that 1-yr results may not have reflected full deferasirox efficacy. Extension data are presented here. Deferasirox starting dose was 20mg/kg/d (increases to 30/40mg/kg/d permitted in the core/extension, respectively). Efficacy was primarily assessed by absolute change in LIC and serum ferritin. Overall, 231 patients received deferasirox in the extension; 67.4% (P

KW - β-thalassaemia

KW - Deferasirox

KW - Efficacy

KW - Iron chelation therapy

KW - Iron overload

UR - http://www.scopus.com/inward/record.url?scp=80053251950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053251950&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2011.01662.x

DO - 10.1111/j.1600-0609.2011.01662.x

M3 - Article

VL - 87

SP - 355

EP - 365

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 4

ER -